AUTHORS
Sonali Chaudhury, MD, Claudi Pagan2, Roland Meisel, MD3, Mohammed Essa4, Haydar Frangoul, MD, MS5, Jonathan D. Fish, MD6, Jaap Jan Boelens, MD, PhD7, David Jacobsohn, MD8, Timothy S. Olson, MD, PhD9, Hemalatha Geetharani Rangarajan I, MD10
AFFILIATIONS
1 Lurie Children's hospital, Northwestern University, Chicago, Illinois, United States
2 Lurie Children's hospital, Northwestern University, Chicago, Illinois, United States
3 Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
4 King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
5 Sarah Cannon Pediatric Hematology/Oncology & Cellular Therapy @TriStar Centennial, Nashville, Tennessee, United States
6 Northwell Health / Cohen Children’s Medical Center, Donald and Barabara Zucker School of Medicine, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, United States
8 Children's National Medical Center, Washington, Maryland, United States
9 Children's Hospital of Philadephia, Philadephia, Pennsylvania, United States
10 Nationwide Children's Hospital, Columbus, Ohio, United States
ABSTRACT
Background: Gene therapy is rapidly transforming the treatment of many non-malignant disorders. As the number of approved and emerging therapies expands, there is an increasing need for collaborative groups that facilitate knowledge sharing, addresses implementation challenges, and generate real-world evidence. The Real-world GENe Therapy Consortium (ReGENT) was established to address this need, creating a collaborative learning environment that brings together diverse stakeholders with a shared mission of improving outcomes for patients with non-malignant disorders undergoing gene therapy.
Methods: We describe the consortium's structure, aims, and objectives, and highlight key successes, challenges, and lessons learned to date.
Results: ReGENT is a newly established multicenter consortium comprising 70 treatment centers across the United States and internationally. The consortium has developed a sustainable learning network through monthly online meetings, case-based discussions and intime query resolutions that promote knowledge exchange, peer mentorship, and dissemination of best current practices. These activities have helped new and growing gene therapy programs benefit from the expertise of established centers
A major academic objective of ReGENT is the development of a comprehensive real-world data repository. By systematically capturing granular data on stem cell harvest, clinical outcomes, treatment-related toxicities, durability of response, and quality of life metrics, ReGENT aims to complement existing registries and facilitate the earlier identification of emerging trends, safety signals, and opportunities to optimize clinical practice.
For example, early data on 40 patients who underwent commercial gene therapy for transfusion-dependent thalassemia (TDT; n=17) and sickle cell disease (SCD; n=23), revealed that TDT patients (median age 13 years, range 3-28) compared to SCD patients (median age 18 years, range 7-36), demonstrated higher post-plerixafor CD34+ counts (162 cells/μL vs 82 cells μL) and required fewer collection cycles (67% completed in 1cycle and 94% in ≤2 cycles vs 46% in 1 cycle, while 21% required ≥3 cycles). CD34+ yield from 70 cycles (46 SCD and 24 TDT) were sent for manufacturing with a higher median dose in TDT patients (37.7 × 106/kg vs 19.8 × 106/kg). Manufacturing failure, (defined as inability to generate a releasable drug product from a mobilized cycle) occurred in 30% (n=7) of TDT and 12% (n=5) of SCD collections, due to inadequate product generation or failure to meet release criteria. Centers are also reporting use of alternative salvage mobilization strategies in patients with SCD: motixafortide in US centers and GCSF in some non-US centers.These early real-world data highlight important differences in mobilization and manufacturing outcomes between disease populations and clinical trials and have identified opportunities to optimize collection strategies and develop predictive models of manufacturing success. Updated data collection in 100+ patients is ongoing
ReGENT also facilitates engagement with industry partners to address manufacturing, operational, and patient-specific challenges. These efforts have accelerated best-practice adoption, advocated for increased collection availability, manufacturing transparency, and enabled centers to share lessons learned in gene therapy delivery.
Despite these accomplishments, important challenges remain. The large size and diverse composition of the consortium present logistical, administrative and financial challenges, particularly as ReGENT transitions from a collaborative learning network to a real-world data generation platform. Establishing governance structures, data-use agreements, regulatory approvals, and standardized data collection processes across institutions remains resource and time intensive. Notably, only 17 centers (24% of all centers) have completed these processes and are participating in the data sharing and collection, highlighting an important operational challenge to broader participation.
Conclusion: The development of a de novo collaborative group around a novel, rapidly expanding therapy is both critical and daunting. By combining collaborative learning, stakeholder engagement, and rapid real-world evidence generation, ReGENT seeks to create a learning health system capable of accelerating improvements in gene therapy delivery and outcomes beyond what can be achieved by individual centers working in isolation.
DISCLOSURES
Hemalatha Geetharani Rangarajan I, MD: EDITAS - Other (including travel support); Medexus - Consultancy (Includes expert testimony); BEAM therapeutics - Consultancy (Includes expert testimony); Vertex Therapeutics - Consultancy (Includes expert testimony); NMDP Data Safety Monitoring Board CD33 CAR T (unpaid) - Consultancy (Includes expert testimony)